Cancer Patients Benefit from mRNA Vaccines, Study Suggests
1,000+ patients studied (180 lung cancer, 43 melanoma) showed survival differences.
Lung cancer patients had 37-month median survival vs 20 months for unvaccinated.
Melanoma patients had 43 vaccinated vs 167 unvaccinated in survival data.
Benefits most pronounced in 'cold' tumors with immune activation and PD-L1.
Study is early and retrospective, requiring further clinical trials.
US cuts mRNA vaccine funding amid research caution.